Skip to main content
TipRanks
Go Ultimate75% OFF

Capricor Therapeutics (0HTB) Stock Statistics & Valuation Metrics

0 Followers

Total Valuation

Capricor Therapeutics has a market cap or net worth of EUR 425.60M. The enterprise value is EUR 445.13M.

Market Cap
EUR 425.60M
Enterprise Value
EUR 445.13M

Share Statistics

Capricor Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
―
Owned by Insiders
0.93%
Owned by Institutions
49.41%

Financial Efficiency

Capricor Therapeutics’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -33.40%.

Return on Equity (ROE)
-0.34
Return on Assets (ROA)
-0.30
Return on Invested Capital (ROIC)
-33.40%
Return on Capital Employed (ROCE)
-0.34
Revenue Per Employee
0
Profits Per Employee
-454.74K
Employee Count
231
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Capricor Therapeutics is -3.04. Capricor Therapeutics’s PEG ratio is 0.08.

PE Ratio
-3.04
PS Ratio
0.00
PB Ratio
2.23
Price to FCF
-3.18
Price to Operating Cash Flow
-3.89
PEG Ratio
0.08

Income Statement

In the last 12 months, Capricor Therapeutics had revenue of 0 and earned -105.04M in profits. Earnings per share was -2.26.

Revenue
0
Gross Profit
0
Operating Income
-108.14M
Pretax Income
-105.04M
Net Income
-105.04M
EBITDA
-100.11M
Earnings Per Share (EPS)
-2.26

Cash Flow

In the last 12 months, operating cash flow was -119.99M and capital expenditures -26.29M, giving a free cash flow of -146.29M billion.

Operating Cash Flow
-119.99M
Free Cash Flow
-146.29M
Free Cash Flow per Share
-2.52

Dividends & Yields

Capricor Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-31.25%
Earnings Yield
-31.39%

Important Dates

Capricor Therapeutics upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 10, 2026
Next Earnings Date
Mar 11, 2027
Ex-Dividend Date
―

Financial Position

Capricor Therapeutics as a current ratio of 9.01, with Debt / Equity ratio of 5.87%

Current Ratio
9.01
Quick Ratio
9.01
Debt to Market Cap
0.00
Net Debt to EBITDA
2.70
Interest Coverage Ratio
-35.51

Taxes

In the past 12 months, Capricor Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Capricor Therapeutics EV to EBITDA ratio is 0.45, with an EV/FCF ratio of -3.53.

EV to Sales
0.00
EV to EBITDA
0.45
EV to Free Cash Flow
-3.53
EV to Operating Cash Flow
-4.30

Balance Sheet

Capricor Therapeutics has EUR 197.58M in cash and marketable securities with EUR 92.23M in debt, giving a net cash position of EUR 105.35M billion.

Cash & Marketable Securities
EUR 197.58M
Total Debt
EUR 92.23M
Net Cash
EUR 105.35M
Net Cash Per Share
―
Tangible Book Value Per Share
EUR 3.61

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Capricor Therapeutics is EUR 25.19, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
EUR 25.19
Price Target Upside
―
Analyst Consensus
Moderate Buy
Analyst Count
8
Revenue Growth Forecast
-100.00%
EPS Growth Forecast
-40.84%

Scores

Smart Score
6
AI Score
―